Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer

NCT00949039 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT00949039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00949039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2009
Completion date
March 31, 2014
Enrollment
101 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gynaecologic or digestive pelvic cancer